Published in Nat Protoc on July 12, 2012
Enhanced effect of combining human cardiac stem cells and bone marrow mesenchymal stem cells to reduce infarct size and to restore cardiac function after myocardial infarction. Circulation (2012) 2.57
Synergistic Effects of Combined Cell Therapy for Chronic Ischemic Cardiomyopathy. J Am Coll Cardiol (2015) 1.86
The advancing field of cell-based therapy: insights and lessons from clinical trials. J Am Heart Assoc (2013) 1.40
Surgical models for cardiac regeneration in neonatal mice. Nat Protoc (2014) 1.18
Durable scar size reduction due to allogeneic mesenchymal stem cell therapy regulates whole-chamber remodeling. J Am Heart Assoc (2013) 1.09
Mesenchymal Stem Cells as a Biological Drug for Heart Disease: Where Are We With Cardiac Cell-Based Therapy? Circ Res (2015) 1.03
Strategies for improving animal models for regenerative medicine. Cell Stem Cell (2013) 0.90
Pig lumbar spine anatomy and imaging-guided lateral lumbar puncture: a new large animal model for intrathecal drug delivery. J Neurosci Methods (2013) 0.89
Decline in cellular function of aged mouse c-kit(+) cardiac progenitor cells. J Physiol (2017) 0.88
Stem cell therapy and breast cancer treatment: review of stem cell research and potential therapeutic impact against cardiotoxicities due to breast cancer treatment. Front Oncol (2014) 0.85
Myocardial fibrosis: biomedical research from bench to bedside. Eur J Heart Fail (2017) 0.84
Genetic architecture of fatty acid composition in the longissimus dorsi muscle revealed by genome-wide association studies on diverse pig populations. Genet Sel Evol (2016) 0.83
Livestock models for exploiting the promise of pluripotent stem cells. ILAR J (2015) 0.80
Pim1 Kinase Overexpression Enhances ckit(+) Cardiac Stem Cell Cardiac Repair Following Myocardial Infarction in Swine. J Am Coll Cardiol (2016) 0.79
Invasive surgery reduces infarct size and preserves cardiac function in a porcine model of myocardial infarction. J Cell Mol Med (2015) 0.79
Myocardial infarction and functional outcome assessment in pigs. J Vis Exp (2014) 0.78
Generation and grafting of tissue-engineered vessels in a mouse model. J Vis Exp (2015) 0.78
Development of a closed-artery catheter-based myocardial infarction in pigs using sponge and lidocaine hydrochloride infusion to prevent irreversible ventricular fibrillation. Physiol Rep (2014) 0.77
The role of large animal studies in cardiac regenerative therapy concise review of translational stem cell research. Korean Circ J (2013) 0.76
Common swine models of cardiovascular disease for research and training. Lab Anim (NY) (2016) 0.75
Growth hormone-releasing hormone agonists reduce myocardial infarct scar in swine with subacute ischemic cardiomyopathy. J Am Heart Assoc (2015) 0.75
Clinical research skills development program in cell-based regenerative medicine. Stem Cells Transl Med (2014) 0.75
The Efficacy of Cardiac Anti-miR-208a Therapy Is Stress Dependent. Mol Ther (2017) 0.75
Preclinical modeling and multimodality imaging of chronic myocardial infarction in minipigs induced by novel interventional embolization technique. EJNMMI Res (2016) 0.75
Detecting Acute Myocardial Infarction by Diffusion-Weighted versus T2-Weighted Imaging and Myocardial Necrosis Markers. Tex Heart Inst J (2016) 0.75
Analysis of region specific gene expression patterns in the heart and systemic responses after experimental myocardial ischemia. Oncotarget (2017) 0.75
Acoustically Active Catheter for Intracardiac Navigation by Color Doppler Ultrasonography. Ultrasound Med Biol (2017) 0.75
Heart disease and stroke statistics--2011 update: a report from the American Heart Association. Circulation (2010) 30.07
Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation (2011) 14.00
Concern Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): initial results of a randomised phase 1 trial. Lancet (2011) 11.45
Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications. Circulation (1990) 9.74
Cardiac repair with intramyocardial injection of allogeneic mesenchymal stem cells after myocardial infarction. Proc Natl Acad Sci U S A (2005) 6.16
Bone marrow mesenchymal stem cells stimulate cardiac stem cell proliferation and differentiation. Circ Res (2010) 5.47
Transendocardial, autologous bone marrow cell transplantation for severe, chronic ischemic heart failure. Circulation (2003) 5.34
Mesenchymal stem cells: biology, pathophysiology, translational findings, and therapeutic implications for cardiac disease. Circ Res (2011) 4.75
Measurement of cardiac function using pressure-volume conductance catheter technique in mice and rats. Nat Protoc (2008) 4.50
Allogeneic mesenchymal stem cells restore cardiac function in chronic ischemic cardiomyopathy via trilineage differentiating capacity. Proc Natl Acad Sci U S A (2009) 4.21
Radiolabeled cell distribution after intramyocardial, intracoronary, and interstitial retrograde coronary venous delivery: implications for current clinical trials. Circulation (2005) 3.61
A quantitative, randomized study evaluating three methods of mesenchymal stem cell delivery following myocardial infarction. Eur Heart J (2006) 3.43
Intramyocardial stem cell injection in patients with ischemic cardiomyopathy: functional recovery and reverse remodeling. Circ Res (2011) 3.23
Intramyocardial transplantation of autologous CD34+ stem cells for intractable angina: a phase I/IIa double-blind, randomized controlled trial. Circulation (2007) 2.88
Catheter-based intramyocardial injection of autologous skeletal myoblasts as a primary treatment of ischemic heart failure: clinical experience with six-month follow-up. J Am Coll Cardiol (2003) 2.56
Transendocardial delivery of autologous bone marrow enhances collateral perfusion and regional function in pigs with chronic experimental myocardial ischemia. J Am Coll Cardiol (2001) 2.22
Comparison of intracoronary and transendocardial delivery of allogeneic mesenchymal cells in a canine model of acute myocardial infarction. J Mol Cell Cardiol (2007) 2.04
Intramyocardial bone marrow cell injection for chronic myocardial ischemia: a randomized controlled trial. JAMA (2009) 1.99
Molecular and cellular mechanisms involved in cardiac remodeling after acute myocardial infarction. J Mol Cell Cardiol (2011) 1.61
Percutaneous intramyocardial stem cell injection in patients with acute myocardial infarction: first-in-man study. Heart (2009) 1.41
Safety and feasibility of autologous myoblast transplantation in patients with ischemic cardiomyopathy: four-year follow-up. Circulation (2005) 1.32
Monitoring of cell therapy and assessment of cardiac function using magnetic resonance imaging in a mouse model of myocardial infarction. Nat Protoc (2007) 1.31
In vivo porcine model of reperfused myocardial infarction: in situ double staining to measure precise infarct area/area at risk. Catheter Cardiovasc Interv (2008) 1.27
Stem cells for myocardial repair with use of a transarterial catheter. Circulation (2009) 1.26
Modeling the growth of the Goettingen minipig. J Anim Sci (2007) 1.24
A rodent model of myocardial infarction for testing the efficacy of cells and polymers for myocardial reconstruction. Nat Protoc (2006) 1.16
The adult Göttingen minipig as a model for chronic heart failure after myocardial infarction: focus on cardiovascular imaging and regenerative therapies. Comp Med (2008) 1.16
Functional and bioenergetic consequences of postinfarction left ventricular remodeling in a new porcine model. MRI and 31 P-MRS study. Circulation (1996) 1.14
Transendocardial autologous bone marrow in chronic myocardial infarction using a helical needle catheter: 1-year follow-up in an open-label, nonrandomized, single-center pilot study (the TABMMI study). Am Heart J (2007) 1.11
Concise review: the role of clinical trials in deciphering mechanisms of action of cardiac cell-based therapy. Stem Cells Transl Med (2011) 1.09
Animal models in the study of myocardial ischaemia and ischaemic syndromes. Cardiovasc Res (1998) 1.02
Determination of the myocardial area at risk with pre- versus post-reperfusion imaging techniques in the pig model. Basic Res Cardiol (2011) 0.97
Electromagnetic guidance for catheter-based transendocardial injection: a platform for intramyocardial angiogenesis therapy. Results in normal and ischemic porcine models. J Am Coll Cardiol (2000) 0.91
Targeted transendocardial therapeutic delivery guided by MRI-x-ray image fusion. Catheter Cardiovasc Interv (2011) 0.89
Relevant radiological anatomy of the pig as a training model in interventional radiology. Eur Radiol (1998) 0.89
Live 3D echo guidance of catheter-based endomyocardial injection. Catheter Cardiovasc Interv (2005) 0.89
Endoventricular transplantation of allogenic skeletal myoblasts in a porcine model of myocardial infarction. J Endovasc Ther (2002) 0.84
Horner syndrome after carotid sheath surgery in a pig: anatomic study of cervical sympathetic chain. Comp Med (2011) 0.83
Development of a preclinical model of ischemic cardiomyopathy in swine. Am J Physiol Heart Circ Physiol (2011) 0.82
Regenerative potential of cardiosphere-derived cells expanded from percutaneous endomyocardial biopsy specimens. Circulation (2007) 8.62
FGF23 induces left ventricular hypertrophy. J Clin Invest (2011) 7.22
Cardiac repair with intramyocardial injection of allogeneic mesenchymal stem cells after myocardial infarction. Proc Natl Acad Sci U S A (2005) 6.16
Bone marrow mesenchymal stem cells stimulate cardiac stem cell proliferation and differentiation. Circ Res (2010) 5.47
Mesenchymal stem cells: biology, pathophysiology, translational findings, and therapeutic implications for cardiac disease. Circ Res (2011) 4.75
Allogeneic mesenchymal stem cells restore cardiac function in chronic ischemic cardiomyopathy via trilineage differentiating capacity. Proc Natl Acad Sci U S A (2009) 4.21
In vivo magnetic resonance imaging of mesenchymal stem cells in myocardial infarction. Circulation (2003) 4.00
Nitric oxide regulates the heart by spatial confinement of nitric oxide synthase isoforms. Nature (2002) 3.92
Disruption of leptin signaling contributes to cardiac hypertrophy independently of body weight in mice. Circulation (2003) 3.30
Intramyocardial stem cell injection in patients with ischemic cardiomyopathy: functional recovery and reverse remodeling. Circ Res (2011) 3.23
Xanthine oxidoreductase and cardiovascular disease: molecular mechanisms and pathophysiological implications. J Physiol (2003) 3.19
Arginase reciprocally regulates nitric oxide synthase activity and contributes to endothelial dysfunction in aging blood vessels. Circulation (2003) 3.01
Mesenchymal stem cells and idiopathic pulmonary fibrosis. Potential for clinical testing. Am J Respir Crit Care Med (2013) 2.66
Inducible NO synthase dependent S-nitrosylation and activation of arginase1 contribute to age-related endothelial dysfunction. Circ Res (2007) 2.62
Enhanced effect of combining human cardiac stem cells and bone marrow mesenchymal stem cells to reduce infarct size and to restore cardiac function after myocardial infarction. Circulation (2012) 2.57
Nitric oxide regulation of myocardial contractility and calcium cycling: independent impact of neuronal and endothelial nitric oxide synthases. Circ Res (2003) 2.44
Knockdown of arginase I restores NO signaling in the vasculature of old rats. Hypertension (2005) 2.37
Autologous mesenchymal stem cells produce reverse remodelling in chronic ischaemic cardiomyopathy. Eur Heart J (2009) 2.29
L-arginine therapy in acute myocardial infarction: the Vascular Interaction With Age in Myocardial Infarction (VINTAGE MI) randomized clinical trial. JAMA (2006) 2.24
Transcriptomic biomarkers for individual risk assessment in new-onset heart failure. Circulation (2008) 2.15
Endogenous S-nitrosothiols protect against myocardial injury. Proc Natl Acad Sci U S A (2009) 2.13
Multimodality noninvasive imaging demonstrates in vivo cardiac regeneration after mesenchymal stem cell therapy. J Am Coll Cardiol (2006) 2.10
Therapeutic drug monitoring for everolimus in heart transplant recipients based on exposure-effect modeling. Am J Transplant (2004) 2.09
Contrast-enhanced multidetector computed tomography viability imaging after myocardial infarction: characterization of myocyte death, microvascular obstruction, and chronic scar. Circulation (2006) 2.07
Mechanisms of action of mesenchymal stem cells in cardiac repair: potential influences on the cardiac stem cell niche. Nat Clin Pract Cardiovasc Med (2007) 2.07
Xanthine oxidoreductase inhibition causes reverse remodeling in rats with dilated cardiomyopathy. Circ Res (2005) 2.05
Inhibition of miR-15 protects against cardiac ischemic injury. Circ Res (2011) 2.02
Characterization and prognostic value of persistent hyponatremia in patients with severe heart failure in the ESCAPE Trial. Arch Intern Med (2007) 1.98
Early improvement in cardiac tissue perfusion due to mesenchymal stem cells. Am J Physiol Heart Circ Physiol (2008) 1.97
Neuronal nitric oxide synthase negatively regulates xanthine oxidoreductase inhibition of cardiac excitation-contraction coupling. Proc Natl Acad Sci U S A (2004) 1.91
Is stem cell therapy ready for patients? Stem Cell Therapy for Cardiac Repair. Ready for the Next Step . Circulation (2006) 1.87
Endomyocardial biopsy plays a role in diagnosing patients with unexplained cardiomyopathy. Am Heart J (2004) 1.84
Deficient ryanodine receptor S-nitrosylation increases sarcoplasmic reticulum calcium leak and arrhythmogenesis in cardiomyocytes. Proc Natl Acad Sci U S A (2007) 1.79
The gene expression profile of patients with new-onset heart failure reveals important gender-specific differences. Eur Heart J (2009) 1.73
Noninvasive diagnosis of biopsy-proven cardiac amyloidosis. J Am Coll Cardiol (2004) 1.70
Imbalance between xanthine oxidase and nitric oxide synthase signaling pathways underlies mechanoenergetic uncoupling in the failing heart. Circ Res (2002) 1.70
Xanthine oxidase inhibition ameliorates cardiovascular dysfunction in dogs with pacing-induced heart failure. J Mol Cell Cardiol (2005) 1.61
Gene expression analysis of ischemic and nonischemic cardiomyopathy: shared and distinct genes in the development of heart failure. Physiol Genomics (2005) 1.54
Mesenchymal stem cells: future source for reparative medicine. Congest Heart Fail (2005) 1.53
Usefulness of immunosuppression for giant cell myocarditis. Am J Cardiol (2008) 1.52
Optimizing rotational atherectomy in high-risk percutaneous coronary interventions: insights from the PROTECT ΙΙ study. Catheter Cardiovasc Interv (2013) 1.50
Identification of a gene expression profile that differentiates between ischemic and nonischemic cardiomyopathy. Circulation (2004) 1.47
Concerted regulation of skeletal muscle contractility by oxygen tension and endogenous nitric oxide. Proc Natl Acad Sci U S A (2003) 1.44
Critical role for the alpha-1B adrenergic receptor at the sympathetic neuroeffector junction. Hypertension (2004) 1.44
Quantitative automated assessment of myocardial perfusion at cardiac catheterization. Am J Cardiol (2008) 1.43
Effects of combination of proliferative agents and erythropoietin on left ventricular remodeling post-myocardial infarction. Clin Transl Sci (2011) 1.43
A clinical and histopathologic comparison of cardiac sarcoidosis and idiopathic giant cell myocarditis. J Am Coll Cardiol (2003) 1.42
The advancing field of cell-based therapy: insights and lessons from clinical trials. J Am Heart Assoc (2013) 1.40
The use of vascular closure devices and impact on major bleeding and net adverse clinical events (NACEs) in balloon aortic valvuloplasty: a sub-analysis of the BRAVO study. Catheter Cardiovasc Interv (2013) 1.40
Management of paravalvular regurgitation after Edwards SAPIEN transcatheter aortic valve replacement: management of paravalvular regurgitation after TAVR. Catheter Cardiovasc Interv (2013) 1.38
Impact of CMS coverage decision on access to transcatheter aortic valve replacement. Catheter Cardiovasc Interv (2014) 1.38
Arginase modulates myocardial contractility by a nitric oxide synthase 1-dependent mechanism. Proc Natl Acad Sci U S A (2006) 1.36
Deficiency of neuronal nitric oxide synthase increases mortality and cardiac remodeling after myocardial infarction: role of nitroso-redox equilibrium. Circulation (2005) 1.35
Impaired S-nitrosylation of the ryanodine receptor caused by xanthine oxidase activity contributes to calcium leak in heart failure. J Biol Chem (2010) 1.35
Nitroso-redox interactions in the cardiovascular system. Circulation (2006) 1.34
Cell-based therapy for prevention and reversal of myocardial remodeling. Am J Physiol Heart Circ Physiol (2012) 1.31
Nitroso-redox balance in the cardiovascular system. N Engl J Med (2004) 1.30
Cardiac myocyte apoptosis is associated with increased DNA damage and decreased survival in murine models of obesity. Circ Res (2005) 1.30
Emerging role for bone marrow derived mesenchymal stem cells in myocardial regenerative therapy. Basic Res Cardiol (2005) 1.28
Cardioprotective effects of growth hormone-releasing hormone agonist after myocardial infarction. Proc Natl Acad Sci U S A (2010) 1.27
Ventricular resynchronization: current state of the art. Circulation (2004) 1.26
Mesenchymal stem cell therapy for cardiac repair. Methods Mol Biol (2010) 1.26
S-nitrosoglutathione reductase (GSNOR) enhances vasculogenesis by mesenchymal stem cells. Proc Natl Acad Sci U S A (2013) 1.20
Pulmonary hypertension and risk of death in cardiomyopathy: patients with myocarditis are at higher risk. Circulation (2002) 1.19
Dynamic denitrosylation via S-nitrosoglutathione reductase regulates cardiovascular function. Proc Natl Acad Sci U S A (2012) 1.18
Inhibition of restenosis with a paclitaxel-eluting, polymer-free coronary stent: the European evaLUation of pacliTaxel Eluting Stent (ELUTES) trial. Circulation (2004) 1.17
The adult Göttingen minipig as a model for chronic heart failure after myocardial infarction: focus on cardiovascular imaging and regenerative therapies. Comp Med (2008) 1.16
Inhibitory G protein overexpression provides physiologically relevant heart rate control in persistent atrial fibrillation. Circulation (2004) 1.15
Inhibition of the SDF-1/CXCR4 axis attenuates neonatal hypoxia-induced pulmonary hypertension. Circ Res (2009) 1.14
Aging impairs the beneficial effect of granulocyte colony-stimulating factor and stem cell factor on post-myocardial infarction remodeling. Circ Res (2006) 1.13
Bone marrow mononuclear cell therapy for acute myocardial infarction: a perspective from the cardiovascular cell therapy research network. Circ Res (2014) 1.12
Uric acid predicts clinical outcomes in heart failure: insights regarding the role of xanthine oxidase and uric acid in disease pathophysiology. Circulation (2003) 1.12
S-Nitrosylation of cardiac ion channels. J Cardiovasc Pharmacol (2009) 1.12
Characterization of peri-infarct zone heterogeneity by contrast-enhanced multidetector computed tomography: a comparison with magnetic resonance imaging. J Am Coll Cardiol (2009) 1.10
Increased potency of cardiac stem cells compared with bone marrow mesenchymal stem cells in cardiac repair. Stem Cells Transl Med (2012) 1.10
Effects of weight loss after bariatric surgery on epicardial fat measured using echocardiography. Am J Cardiol (2007) 1.10
Durable scar size reduction due to allogeneic mesenchymal stem cell therapy regulates whole-chamber remodeling. J Am Heart Assoc (2013) 1.09
Characterization of uptake of the new PET imaging compound 18F-fluorobenzyl triphenyl phosphonium in dog myocardium. J Nucl Med (2006) 1.09
Concise review: the role of clinical trials in deciphering mechanisms of action of cardiac cell-based therapy. Stem Cells Transl Med (2011) 1.09
Mesenchymal stem cell labeling and in vitro MR characterization at 1.5 T of new SPIO contrast agent: Molday ION Rhodamine-B™. Contrast Media Mol Imaging (2010) 1.09